Skip to content

Italian Registry Chronic Pancreatitis

Registro Italiano Pancreatite Cronica

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05733130
Acronym
ITARECIPE
Enrollment
1500
Registered
2023-02-17
Start date
2022-10-10
Completion date
2027-12-31
Last updated
2024-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pancreatitis

Keywords

chronic pancreatitis, surveillance chronic pancreatitis, chronic pancreatitis diagnosis, chronic pancreatitis therapy

Brief summary

ITARECIPE is a multicenter national registry designed to study the diagnosis and evolution of Chronic Pancreatitis

Detailed description

Chronic pancreatitis (PC) is a relatively rare disease (45/100,000 population) in Italy, with heterogeneous aetiology, clinical history and treatment. Patients need to be treated by different specialists, but almost always the gastroenterologist is central in diagnosis and treatment. The study will be the first National Registry, prospective and will collect data on the history of the disease and its outcomes. Data will be collected through an electronic data collection form (e-CRF) that the Sponsor (AISP) will make available to the Participating Centres. Patients enrolled will be both new diagnoses or follow-up visits of patients with a diagnosis already made no more than 1 year before the signing of informed consent for the study in question: only data on the diagnosis and follow-up visits prior to the signing of the informed consent will be collected retrospectively (no more than one year). Data from patients visited in the Centres included in the study will be collected prospectively. In addition to the first visits, data will also be collected on follow-up visits that are scheduled according to the clinical need of each patient, which differ according to the stage of the disease

Interventions

None listed

Sponsors

Associazione Italiana per lo Studio del Pancreas
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>/= 12 years; * Diagnosis definite or probable according to the M-ANNHEIM criteria; * First evidence of diagnosis within 12 months of enrolment.

Exclusion criteria

* Age \< 12 years; * History of known disease with certainty for \> 12 months.

Design outcomes

Primary

MeasureTime frameDescription
Disease Progression5 yearsThe collection of data on disease progression in terms of the need for medical, endoscopic or surgical therapy, the risk of pancreatic exo-endocrine failure and the risk of developing pancreatic and extrapancreatic complications and death.

Countries

Italy

Contacts

Primary ContactGabriele Capurso, PhD
capurso.gabriele@hsr.it00390226436548

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026